Stockscreener 앱 받기
24.42
0.41%
0.10
시장 영업 전:
24.48
0.06
+0.25%
전일 마감가:
$24.32
열려 있는:
$24.36
하루 거래량:
209.77K
Relative Volume:
0.60
시가총액:
$1.01B
수익:
-
순이익/손실:
$-136.98M
주가수익비율:
-6.0746
EPS:
-4.02
순현금흐름:
$-126.63M
1주 성능:
-1.09%
1개월 성능:
+20.89%
6개월 성능:
+3.34%
1년 성능:
-5.64%
1일 변동 폭
$23.52
$24.78
1주일 범위
$23.29
$25.82
52주 변동 폭
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
AVBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
24.42 | 1.00B | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why (AVBP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential - Investing.com Canada
ArriVent Biopharma initiated with a Buy at BTIG - TipRanks
BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - news.stocktradersdaily.com
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Will ArriVent BioPharma Inc. stock sustain high P E ratiosWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
A new trading data show ArriVent BioPharma Inc (AVBP) is showing positive returns. - Setenews
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent Biopharma initiated with a Buy at Truist - TipRanks
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug - Investing.com Canada
Truist Initiates ArriVent BioPharma at Buy With $43 Price Target - marketscreener.com
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Avoiding Lag: Real-Time Signals in (AVBP) Movement - news.stocktradersdaily.com
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam - MSN
Is ArriVent BioPharma Inc. stock in correction or buying zoneCEO Change & Smart Money Movement Alerts - newser.com
Can ArriVent BioPharma Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Momentum Based Trading Signals - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stockJuly 2025 Big Picture & Smart Swing Trading Alerts - newser.com
How institutional ownership impacts ArriVent BioPharma Inc. stockWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will ArriVent BioPharma Inc. stock gain from lower inflationWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & High Yield Equity Trading Tips - newser.com
Can momentum traders help lift ArriVent BioPharma Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Published on: 2025-11-19 02:02:03 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 20252025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Why Red River Bancshares, Inc. stock attracts strong analyst attention - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio chartsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-15 15:01:05 - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension fundsLong Setup & Accurate Entry/Exit Alerts - newser.com
Momentum divergence signals in ArriVent BioPharma Inc. chartWeekly Stock Recap & Real-Time Volume Analysis - newser.com
What is the fair value of ArriVent BioPharma Inc. stock now2025 Earnings Impact & Fast Gain Stock Tips - Fundação Cultural do Pará
What is HC Wainwright’s Forecast for AVBP FY2025 Earnings? - Defense World
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):